Board of Directors
Dr. Adams has more than 30 years of experience in drug discovery and development with a strong focus on cancer research. Dr Adams, recently joined CureTech as Chairman, and serves Clal Biotechnology Industries as its Chief Scientific Officer and President. He was previously president of research and development at Infinity Pharmaceuticals. Prior to joining Infinity in 2003, Dr. Adams was the senior vice president of drug discovery and development at Millennium Pharmaceuticals, where he headed multiple global drug discovery and development programs, including the successful Velcade® (bortezomib) program. Dr. Adams also held senior positions in research and development at LeukoSite (acquired by Millennium) and at ProScript, as well as in medicinal chemistry at Boehringer Ingelheim, where he is credited with discovering Viramune® (nevirapine) for HIV. Dr. Adams has won many awards, holds 40+ patents and has authored more than 100 papers and book chapters in peer-reviewed journals. He earned a B.S. from McGill University and a Ph.D. from the Massachusetts Institute of Technology. He also received a Doctor of Science, honoris causa, from McGill University in 2012.
Llew Keltner, M.D., Ph.D., has a 30-year career in biopharma drug and business development. He is Chief Executive Officer of EPISTAT, an international healthcare technology transfer, corporate risk management and healthcare strategy company that he founded in 1972. Dr. Keltner was the Chief Executive Officer of AgonOx, a biotech company developing OX40 agonists for use in cancer therapy, from 2011 to 2013. He was the President of Novici Biotech, a privately-held gene and protein optimization firm in 2010 and 2011. Dr. Keltner was Chief Executive Officer and President of Light Sciences Oncology, a privately-held biotechnology company developing a late stage, light-activated therapy for hepatocellular cancer and other solid tumors from 2001 to 2010. From 1997 to 2004, Dr. Keltner was Chief Executive Officer of Metastat, a development-stage biotech company focused on cancer metastasis.
Dr. Keltner holds positions on the boards of BioQ Pharma and Goodwell Technologies. He is a previous Director and Chairman of Raptor Pharmaceuticals (NASDAQ:RPTP) and Director Light Sciences Corporation, Vital Choice, Thesis Technologies, Oread Companies, and MannKind Corporation (NASDAQ:MNKD). He has also been a scientific advisory board member at Lifetime Corporation, ASB Meditest, Oread Laboratories, Hall-Kimbrell, and aai Pharma. Dr. Keltner is an Associate Professor at Case Western Reserve School of Medicine, and a Guest Lecturer and Director in the Bioethics Program at Columbia University School of Medicine. He is currently a member of the American Society of Clinical Oncology, American Medical Association, International Association of Tumor Marker Oncology, American Association of Clinical Chemistry, and Drug Information Association. Dr. Keltner received an M.S. in Epidemiology and Biostatistics, a Ph.D. in Biomedical Informatics and an M.D. from Case Western Reserve University in Cleveland, Ohio. Dr. Keltner has also authored many research publications.
Ofer Gonen is the Acting CEO of Clal Biotechnology Industries (CBI) and manages life sciences investments, business development, US-based operations, and investment support for CBI's portfolio companies. Mr. Gonen serves as an executive chairman and board member of several companies including Gamida Cell, MediWound (NASDAQ: MDWD), Campus Bio and CLS.
Prior to joining CBI, Mr. Gonen was the general manager of Biomedical Investments as well as a technology consultant to various Israeli venture capital funds and an Academic Aide to the Governor of the Bank of Israel. Mr. Gonen gained extensive experience in R&D and management in defense-oriented projects within the prestigious “TALPIOT” program of the Israeli Defence Forces, for which he was awarded the Israeli National Security Medal.
Mr. Gonen holds an M.A. in Economics and Finance from the Tel Aviv University, and a B.Sc. in Physics, Mathematics and Chemistry from the Hebrew University in Jerusalem.
For the past fifteen years, Mr. Goldberg has been actively involved with healthcare related companies ranging in stage from inception to commercialization. Mr. Goldberg is responsible for strategic investment decisions and technological development of Clal Biotechnology Industries (CBI). Mr. Goldberg is also the managing director of Anatomy Medical Technology fund, CBI’s medical device investment arm.
Mr. Goldberg serves as an executive chairman and board member of several biotech and medical device companies, among them Biocancell (TASE: BICL), Pi-Cardia, Cologuard, Biokine and SightDX.
Mr. Goldberg holds an M.A. in Economics and Finance from Tel Aviv University and a B.Sc. in Physics and Mathematics from the Hebrew University of Jerusalem.
Stay tuned and get all
the latest updates
© Cure Tech 2016 | All Rights Reserved | Legal Disclaimer